BAY 11-7082
别名: BAY 11-7821
BAY 11-7082 (BAY 11-7821)是一种 NF-κB 抑制剂，抑制TNFα诱导的 IκBα 磷酸化，在肿瘤细胞中IC50为10 μM。BAY 11-7082 可抑制 ubiquitin-specific protease USP7 和 USP21，对应的IC50值分别为0.19 μM和0.96 μM。BAY 11-7082 在胃癌细胞中可诱导凋亡和S期阻滞。
BAY 11-7082 Chemical Structure
CAS: 19542-67-7
产品质控
批次：
纯度：
99.98%
99.98
BAY 11-7082相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| SP6.5 | Growth Inhibition Assay | 2.5-20 μM | 24 h | IC50=5 μM, exhibits strong anti-proliferative effects in a dose-dependent manner | 23443086 |
| OM431 | Function Assay | 5 μM | 2 h | decreases translocation of p65 in the nucleus | 23443086 |
| OCM1 | Function Assay | 5 μM | 2 h | decreases translocation of p65 in the nucleus | 23443086 |
| VUP | Function Assay | 5 μM | 2 h | decreases translocation of p65 in the nucleus | 23443086 |
| SP6.5 | Function Assay | 5 μM | 2 h | decreases translocation of p65 in the nucleus | 23443086 |
| BAFs | Function Assay | 0.5/1 μM | 24 h | inhibits TNFα/DEX induced CYP19A1 transcripts | 23485457 |
| KMS-12-BM | Apoptosis Assay | 30 µM | 3 h | induces MM cell death involves necrosis | 23527154 |
| MM.1S | Apoptosis Assay | 30 µM | 3 h | induces MM cell death involves necrosis | 23527154 |
| HT29 | Function Assay | 10/30/100 μM | 1 h | inhibits TNF-induced phosphorylation and degradation of IκBα | 23527154 |
| HT29 | Function Assay | 10/30/100 μM | 1 h | inhibites both TWEAK-induced p100 processing | 23527154 |
| HUVEC | Function Assay | 10 μM | 0.5 h | counteractes the loss of Tie2 mRNA | 23563632 |
| RAW 264 | Function Assay | 0.2-5 µM | 30/60/90 min | inhibits the phosphatase activity of PTP1B | 23578302 |
| AM | Growth Inhibition Assay | 5 µM | 4/8 d | reduces the viability of intracellular MTB | 23634218 |
| MDM | Growth Inhibition Assay | 5 µM | 4/8 d | reduces the viability of intracellular MTB | 23634218 |
| THP-1 | Growth Inhibition Assay | 5 µM | 4/8 d | reduces the viability of intracellular MTB | 23634218 |
| THP-1 | Function Assay | 5 µM | 1 h | inhibits MTB-induced NFκB activation | 23634218 |
| HepG2 | Function Assay | 0.3/1/3 μM | 48 h | reduces IL6-induced PON1 expression | 23791833 |
| HBE | Function Assay | 10μM | 3h | abolishes the increases of IL-6 expression induced by CSE | 23824089 |
| HGC-27 | Apoptosis Assay | 7.5/15/30 μM | 6 h | induces apoptosis in a time- and dose-dependent manner | 23846545 |
| MGC80-3 | Function Assay | 7.5/15/30 μM | 6 h | induces the dephosphorylation and up-regulation of IκBα | 23846545 |
| HGC-27 | Function Assay | 7.5/15/30 μM | 6 h | induces the dephosphorylation and up-regulation of IκBα | 23846545 |
| MGC80-3 | Growth Inhibition Assay | 10/20/30 μM | 6/24 h | suppresses cell viability significantly | 23846545 |
| AGS | Growth Inhibition Assay | 10/20/30 μM | 6/24 h | suppresses cell viability significantly | 23846545 |
| NCI-N87 | Growth Inhibition Assay | 10/20/30 μM | 6/24 h | suppresses cell viability significantly | 23846545 |
| A549 | Apoptosis Assay | 1 μM | 48 h | reduces the cell death induced by combined stimulation | 23900080 |
| A549 | Function Assay | 1 μM | 48 h | enhances the up-regulation of IκB and subsequent decrease in Bax expression induced by combined stimulation | 23900080 |
| THP-1 | Function Assay | 10 μM | 1 h | abolishes the effect of rHSP27 on SR-A mRNA | 23939398 |
| PC-3 | Function Assay | 2.5/5/10 μM | 0.5 h | blocks IGF-II-induced STS mRNA expression | 24055520 |
| iNKT | Function Assay | 10/100 μM | 0.5 h | inhibits the induction of A2AR mRNA and other factor | 24124453 |
| IVD | Function Assay | 10 μM | 3 d | abrogates TNF-α–induced up-regulation of ADAMTS-4 and ADAMTS-5 | 24176808 |
| IVD | Function Assay | 10 μM | 3 d | reverses TNF-α–mediated suppression of the disc matrix macromolecules aggrecan and collagen II | 24176808 |
| A549RT-eto | Function Assay | 10 μM | 24 h | decreases the expression levels of NF-κB and P-gp | 24220725 |
| A549RT-eto | Apoptosis Assay | 10 μM | 24 h | accelerates F14 extract-mediated apoptosis combined treatment with F14 | 24220725 |
| WPs | Function Assay | 25 μM | 5 min | suppresses ATP and vWF secretion | 24331207 |
| DSCs | Function Assay | 2.5 μM | 0.5 h | reverses the enhancement of CCL2/CCR2 expression of DSCs induced by IL-33 | 24344240 |
| OVCXCR2 | Function Assay | 2 µM | 48 h | blocks the CXCL1-induced cell invasion | 24376747 |
| SKCXCR2 | Function Assay | 2 µM | 48 h | blocks the CXCL1-induced cell invasion | 24376747 |
| SKCXCR2 | Growth Inhibition Assay | 2 µM | 48 h | decreases cell proliferation significantly | 24376747 |
| THP-1 | Function Assay | 0.1/1 μM | 0.5 h | abrogates TNF-α secretion as well as the increased secretion of IL-6 and IL-1β | 24378536 |
| A549RT-eto | Apoptosis Assay | 10 μM | 24 h | accelerates FERO-mediated apoptosis | 24535083 |
| HUVEC | Function Assay | 20 µM | 0.5 h | prevents the induction of EAM expression | 24551209 |
| A549 | Function Assay | 10 μM | 1 h | inhibits the increase of phospho-IκBα in PA103-infected cultures | 24612488 |
| HeLa | Function Assay | 5 μM | 24 h | reduces the activity of TNF-α promoter | 24657783 |
| HUVECs | Function Assay | 3-30 μM | 1 h | reduces the expression of miR-146a in a dose-dependent manner | 24863965 |
| macrophages | Function Assay | 5 µM | 3 h | partially blocks YPFS-induced expression of iNOS and COX-2 | 24967898 |
| RAW 264.7 | Function Assay | 5 μM | 1 h | inhibits TNF-α and IL-12 p40 production | 25019567 |
| A549 | Function Assay | 10 µM | 12 h | suppresses Dvl-3 induced activation of p65 | 25156800 |
| HMECs | Function Assay | 5 μM | 2 h | abolishes TNF-α-induced VCAM-1 expression | 25193116 |
| HCT116 | Function Assay | 5 μM | 2 h | attenuates silymarin-induced downregulation of cyclin D1 | 25479723 |
| ARPE-19 | Function Assay | 1 μM | 0.5 h | suppresses TG-induced IL-8 promoter activation | 25593029 |
| SiHa | Function Assay | 10 μM | 1.5 h | abolishes BPA induced up regulation of FN and MMP-9 | 25797437 |
| HeLa | Function Assay | 10 μM | 1.5 h | abolishes BPA induced up regulation of FN and MMP-9 | 25797437 |
| VUP | Growth Inhibition Assay | 2.5-20 μM | 24 h | IC50=5 μM, exhibits strong anti-proliferative effects in a dose-dependent manner | 23443086 |
| OCM1 | Growth Inhibition Assay | 2.5-20 μM | 24 h | IC50=5 μM, exhibits strong anti-proliferative effects in a dose-dependent manner | 23443086 |
| OM431 | Growth Inhibition Assay | 2.5-20 μM | 24 h | IC50=5 μM, exhibits strong anti-proliferative effects in a dose-dependent manner | 23443086 |
| SP6.5 | Apoptosis Assay | 5 μM | 24 h | induces apoptosis | 23443086 |
| VUP | Apoptosis Assay | 5 μM | 24 h | induces apoptosis | 23443086 |
| OCM1 | Apoptosis Assay | 5 μM | 24 h | induces apoptosis | 23443086 |
| OM431 | Apoptosis Assay | 5 μM | 24 h | induces apoptosis | 23443086 |
| SP6.5 | Function Assay | 5 μM | 12 h | reduces the migration | 23443086 |
| VUP | Function Assay | 5 μM | 12 h | reduces the migration | 23443086 |
| OCM1 | Function Assay | 5 μM | 12 h | reduces the migration | 23443086 |
| OM431 | Function Assay | 5 μM | 12 h | reduces the migration | 23443086 |
| HBL-1 | Growth Inhibition Assay | 3 μM | 24/48/72 h | slows cell growth modestly | 23441730 |
| RAW 264.7 | Function Assay | 2-15 μM | 1 h | suppresses the activation of IKK family members | 23441730 |
| IL-1R | Function Assay | 2-15 μM | 1 h | suppresses the activation of IKK family members | 23441730 |
| RAW 264.7 | Function Assay | 15 μM | 1 h | suppresses the activation of and JNK | 23441730 |
| IL-1R | Function Assay | 15 μM | 1 h | suppresses the activation of and JNK | 23441730 |
| U2OS | Function Assay | 15 μM | 1 h | prevents the LPS- or IL-1-stimulated formation of K63-pUb chains | 23441730 |
| MT‐1 | Function Assay | 8 µm | 3 h | decreases the levels of p‐STAT3 and p‐4EBP1 | 23278479 |
| MT‐2 | Function Assay | 8 µm | 3 h | decreases the levels of p‐STAT3 and p‐4EBP1 | 23278479 |
| MT‐1 | Function Assay | 8 µm | 3 h | decreases the levels of the p65 subunit of NF‐κB | 23278479 |
| MT‐2 | Function Assay | 8 µm | 3 h | decreases the levels of the p65 subunit of NF‐κB | 23278479 |
| MCF-7 | Function Assay | 2.5-15 μM | 0.5 h | causes the gradual loss of cell adhesion | 23093227 |
| HaCaT | Function Assay | 5.0 μM | 1 h | attenuates the TCOH-induced production of IL-6 | 23041168 |
| OA chondrocytes | Function Assay | 10 μM | 1 h | blocks the AGE-BSA-induced gene/protein expression of GRP78 or COX-2 (p<0.05) | 22982228 |
| RAW264.7 | Function Assay | 15 μM | 15-120 min | blocks the production of NO, PGE2, and TNF-α | 22745523 |
| RAW264.7 | Growth Inhibition Assay | 5-30 μM | 24 h | inhibits cell growth in a dose-dependent manner | 22745523 |
| HBL6 | Apoptosis Assay | 0.5/5/25 μM | 6/24 h | decreases cell viability and leeads to apoptosis in a dose-dependent manner | 22074820 |
| HT29 | Function Assay | 1-10 μM | 10 h | increases HO-1 mRNA and protein expression | 21620964 |
| Ca9–22 | Apoptosis Assay | 10 μM | 1 h | completely inhibits ALA-PDT-induced apoptosis | 21138480 |
| Ca9–22 | Function Assay | 10 μM | 1 h | completely abrogates the ALA-PDT-induced JNK activation | 21138480 |
| A-549 | Growth Inhibition Assay | 10 μM | 24/48 h | inhibits cell growth in a time-dependent manner | 20866043 |
| AP | Function Assay | 5/10 μM | 48 h | downregulates the BAD protein level a dose-dependent manner | 20596645 |
| AQ1 | Function Assay | 5/10 μM | 48 h | downregulates the BAD protein level a dose-dependent manner | 20596645 |
| AP | Function Assay | 20 μM | 4/8 h | downregulates the BAD protein level a time-dependent manner | 20596645 |
| AQ1 | Function Assay | 20 μM | 4/8 h | downregulates the BAD protein level a time-dependent manner | 20596645 |
| THP-1 | Function Assay | 5 μM | 0.5 h | attenuates the LPS-induced p-IκBα protein by 72% | 20309718 |
| K562 | Growth Inhibition Assay | 2-30 μM | 24 h | IC50=8 μM,inhibits cell growth in a dose-dependent manner | 19646807 |
| Jurket | Growth Inhibition Assay | 2-30 μM | 24 h | IC50=7.1 μM, inhibits cell growth in a dose-dependent manner | 19646807 |
| U937 | Growth Inhibition Assay | 2-30 μM | 24 h | IC50=10.5 μM, inhibits cell growth in a dose-dependent manner | 19646807 |
| PBMC | Growth Inhibition Assay | 2-30 μM | 24 h | IC50=40.2 μM, inhibits cell growth in a dose-dependent manner | 19646807 |
| K562 | Apoptosis Assay | 2-20 μM | 24 h | induces a dose-dependent apoptosis | 19646807 |
| HEK293 | Function assay | 20 uM | 24 hrs | Inhibition of TNF-alpha stimulated NFkappaB transactivation in HEK293 cells at 20 uM measured after 24 hrs by dual luciferase reporter gene assay | 27736063 |
| RAW264.7 | Function assay | 20 uM | 1 hr | Inhibition of LPS-induced NFkB activation in mouse RAW264.7 cells assessed as reduction in nuclear translocation of p65 at 20 uM preincubated for 1 hr followed by LPS stimulation measured after 3 hrs by Western blot method | 28667873 |
| RAW264.7 | Function assay | 20 uM | 6 hrs | Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells at 20 uM treated 30 mins before LPS challenge measured after 6 hrs by luciferase reporter gene assay | 24315191 |
| RAW264.7 | Antinflammatory assay | 20 uM | 18 hrs | Antinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 20 uM treated 30 mins before LPS challenge measured after 18 hrs by Griess assay | 24315191 |
| THP1 | Antinflammatory assay | 5 uM | 24 hrs | Antiinflammatory activity in human THP1 cells assessed as inhibition of TPA/ionomycin-induced extracellular IL-1beta level at 5 uM incubated 1 hr prior to TPA/ionomycin challenge measured after 24 hrs by ELISA | 24400858 |
| THP1 | Antinflammatory assay | 5 uM | 24 hrs | Antiinflammatory activity in human THP1 cells assessed as inhibition of TPA/ionomycin-induced extracellular TNF-alpha production at 5 uM incubated 1 hr prior to TPA/ionomycin challenge measured after 24 hrs by ELISA | 24400858 |
| THP1 | Antinflammatory assay | 5 uM | 24 hrs | Antiinflammatory activity in human THP1 cells assessed as inhibition of TPA/ionomycin-induced intracellular proIL-1beta level at 5 uM incubated 1 hr prior to TPA/ionomycin challenge measured after 24 hrs by ELISA | 24400858 |
| THP1 | Antinflammatory assay | 5 uM | 24 hrs | Antiinflammatory activity in human THP1 cells assessed as inhibition of TPA/ionomycin-induced intracellular IL-1beta level at 5 uM incubated 1 hr prior to TPA/ionomycin challenge measured after 24 hrs by ELISA | 24400858 |
| RAW264.7 | Function assay | 0.3 ug/ml | 12 hrs | Inhibition of LPS-induced NF-kB p65 phosphorylation in mouse RAW264.7 cells at 0.3 ug/ml preincubated for 12 hrs followed by LPS stimulation for 3 hrs by Western blot method | 28284806 |
| RAW264.7 | Function assay | 0.3 ug/ml | 12 hrs | Inhibition of LPS-induced NF-kB p65 activation in mouse RAW264.7 cells at 0.3 ug/ml preincubated for 12 hrs followed by LPS stimulation for 3 hrs by DAPI staining based inverted fluorescence microscopic method | 28284806 |
| RAW264.7 | Function assay | 0.3 ug/ml | 12 hrs | Inhibition of NF-kB p65 in mouse RAW264.7 cells assessed as reduction in LPS-induced iNOS expression at 0.3 ug/ml preincubated for 12 hrs followed by LPS stimulation for 3 hrs by Western blot method | 28284806 |
| RAW264.7 | Function assay | 0.3 ug/ml | 12 hrs | Inhibition of NF-kB p65 in mouse RAW264.7 cells assessed as reduction in LPS-induced COX2 expression at 0.3 ug/ml preincubated for 12 hrs followed by LPS stimulation for 3 hrs by Western blot method | 28284806 |
| HEK293 | Function assay | 20 uM | 24 hrs | Inhibition of TNFalpha-induced NFkappaB activation in HEK293 cells at 20 uM after 24 hrs by dual luciferase reporter gene assay | 28873303 |
| RAW264.7 | Function assay | 20 uM | 2 hrs | Inhibition of NFkappaB nuclear translocation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated for 2 hrs followed by LPS-induction by DAPI-staining based immunofluorescence microscopic method | 29759725 |
| BGC823 | Function assay | 5 uM | 12 hrs | Inhibition of colony formation in human BGC823 cells at 5 uM treated for 12 hrs followed by incubation in drug free medium for 14 days by crystal violet staining based assay | 28881286 |
| SGC7901 | Function assay | 5 uM | 12 hrs | Inhibition of colony formation in human SGC7901 cells at 5 uM treated for 12 hrs followed by incubation in drug free medium for 14 days by crystal violet staining based assay | 28881286 |
| RAW264.7 | Function assay | 10 uM | 2 hrs | Inhibition of LPS-induced IL-6 mRNA expression in mouse RAW264.7 cells at 10 uM pre-incubated for 2 hrs before LPS stimulation for 24 hrs by qRT-PCR method | 27038497 |
| RAW264.7 | Function assay | 10 uM | 2 hrs | Inhibition of LPS-induced IL-1beta mRNA expression in mouse RAW264.7 cells at 10 uM pre-incubated for 2 hrs before LPS stimulation for 24 hrs by qRT-PCR method | 27038497 |
| RAW264.7 | Function assay | 10 uM | 2 hrs | Inhibition of LPS-induced iNOS mRNA expression in mouse RAW264.7 cells at 10 uM pre-incubated for 2 hrs before LPS stimulation for 24 hrs by qRT-PCR method | 27038497 |
| FaDu | Function Assay | 2 h | inhibits p65 expression and blocks TNFα-induced TWIST expression | 24220622 | |
| A549 | Function Assay | 1 h | inhibits LTA-induced SP-A mRNA production significantly | 23031213 | |
| THP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay, TC50 = 1.5 μM. | 28410442 | |
| RAW264.7 | Function assay | 6 hrs | Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells treated 30 mins before LPS challenge measured after 6 hrs by luciferase reporter gene assay, IC50 = 1.72 μM. | 24315191 | |
| HEK293 | Function assay | 6 hrs | Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay, IC50 = 2 μM. | 24533857 | |
| HEK293 | Function assay | 6 hrs | Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay, IC50 = 2 μM. | 24992702 | |
| HEK293 | Function assay | 6 hrs | Inhibition of TNFalpha-induced NF-kappaB activity (unknown origin) transfected in HEK293 cells after 6 hrs by luciferase reporter gene assay, IC50 = 2 μM. | 26343828 | |
| HEK293 | Function assay | 6 hrs | Inhibition of TNFalpha-induced NF-kappaB activity expressed in human HEK 293 cells after 6 hrs by luciferase reporter gene assay, IC50 = 2 μM. | 22850207 | |
| HEK293 | Function assay | 6 hrs | Inhibition of TNFalpha-induced human NFkappaB activity in HEK293 cells incubated for 6 hrs followed by compound wash out measured after 5 mins by by luciferase assay, IC50 = 2.01 μM. | 22712432 | |
| HEK293 | Function assay | 6 hrs | Inhibition of TNFalpha-induced NFkappaB (unknown origin) activation expressed in HEK293 cells after 6 hrs by luciferase reporter gene assay, IC50 = 5 μM. | 23316950 | |
| HEK293 | Cytotoxicity assay | Cytotoxicity against HEK293 cells, IC50 = 3.8 μM. | 24533857 | ||
| HEK293 | Function assay | Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay | 16680159 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | BAY 11-7082 (BAY 11-7821)是一种 NF-κB 抑制剂，抑制TNFα诱导的 IκBα 磷酸化，在肿瘤细胞中IC50为10 μM。BAY 11-7082 可抑制 ubiquitin-specific protease USP7 和 USP21，对应的IC50值分别为0.19 μM和0.96 μM。BAY 11-7082 在胃癌细胞中可诱导凋亡和S期阻滞。 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | BAY 11-7082完全且特异性地废除 NF-κB DNA结合, 下调NF-κB-诱导的细胞因子IL-6，且诱导细胞凋亡。[1] BAY 11-7082 (< 8 μM) 有效抑制原有的和TNFα 刺激的NF-κB荧光素酶活性，这种作用存在剂量依赖性。BAY 11-7082 (8 μM) 强抑制NCI-H1703 细胞增殖。 [2] Bay 11-7082 (5 μM)作用于感染HTLV-I的T细胞系，快速且有效的降低NF-κB的DNA结合力，且下调抗凋亡基因Bcl-x(L)的表达,而对另一种转录因子AP-1与DNA结合没有作用效果。Bay 11-7082诱导原代ATL细胞发生凋亡比正常的外周血单核细胞更明显，而诱导的这些细胞凋亡也与NF-κB活性的下调相关。Bay 11-7082 (5 μM) 选择性诱导感染HTLV-I的T细胞系发生细胞凋亡，且下调 cyclin D1, cyclin D2, 和 Bcl-xL的表达。 [3] BAY 11-7082 (100 μM)作用于小鼠海马脑片区，抑制NMDA引起的p65发生 核易位，也抑制NMDA诱导的NF-κB结合力的增强。BAY 11-7082抑制NMDA毒性发生在海马脑片区的CA1区，20 μM时，对40％神经有保护作用，100 μM时，对70％神经有保护作用。[4] 作用于脂肪组织，实验中所有浓度的BAY 11-7082都显著抑制 NF-κB p65 DNA结合活性，而作用于骨骼肌，只有50 μM 和 100 μM 的BAY 11-7082显著抑制NF-κB p65 DNA结合活性。BAY 11-7082 (100 μM) 作用于人体脂肪组织和骨骼肌，降低IKK-β蛋白。BAY 11-7082 (100 μM) 显著降低TNF-α从动物脂肪组织中释放，而 IL-6 和 IL-8 的释放显著抑制实验中BAY 11-7082的所有浓度。 BAY 11-7082 (50 μM)作用于骨骼肌，显著降低 TNF-α, IL-6, 和IL-8 的释放。[5] 此外，BAY 11-7082还被发现抑制了 E2-conjugating酶和E3 ligase酶的活性，从而诱导了B-淋巴癌细胞和T淋巴癌细胞的死亡。 [6] |
|||
|---|---|---|---|---|
| 细胞实验 | 细胞系 | NCI-H1703 细胞 | ||
| 浓度 | ~8 μM | |||
| 孵育时间 | 12 小时 | |||
| 方法 | 细胞在96孔板中转染siRNA，然后在完全NSCLC 培养基中培养72小时，再使用BAY 11-7082 处理12小时。细胞与[3H]胸甘温育3小时。使用自动细胞收集器将细胞收集到过滤器上，然后通过β-闪烁计数法测量放射性。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | p-IRAK4 / IRAK4 p-IKKβ/ IκBα NF-κB p-IRAK4 / IRAK4 p-IKKβ/ IκBα NF-κB |
|
23441730 | |
| Growth inhibition assay | Cell viability Cell viability |
|
31332209 | |
化学信息&溶解度
| 分子量 | 207.25 | 分子式 | C10H9NO2S |
| CAS号 | 19542-67-7 | SDF | Download BAY 11-7082 SDF |
| Smiles | CC1=CC=C(C=C1)S(=O)(=O)C=CC#N | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 41 mg/mL ( (197.82 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 10 mg/mL (48.25 mM) Water : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
